Verpasep caltespen clinical trials
Also written HspE7 and SGN-00101.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2001
How each study uses verpasep caltespen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2004 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 3 |
| 2007 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 5
National Cancer Institute (NCI) (3) · Nventa Biopharmaceuticals Corporation (2) · Albert Einstein College of Medicine (1) · Dana-Farber/Brigham and Women's Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses verpasep caltespen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial NeoplasiaCompletedPhase 2Albert Einstein College of MedicineNCT00075569Written as HspE7
- SGN-00101 in Treating Patients With Cervical Intraepithelial NeoplasiaStatus unknownPhase 2Dana-Farber/Brigham and Women's Cancer CenterNCT00060099Written as HspE7
- SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical CellsCompletedPhase 2National Cancer Institute (NCI)NCT00091130Written as HspE7
- SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal NeoplasiaCompletedPhase 1/2National Cancer Institute (NCI)NCT00052897Written as HspE7
- Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial NeoplasiaCompletedPhase 2National Cancer Institute (NCI)NCT00054041Written as HspE7
- Safety Study to Test the Safety of HspE7 and Poly-ICLC Given in Patients With Cervical Intraepithelial NeoplasiaStatus unknownPhase 1Nventa Biopharmaceuticals CorporationNCT00493545Written as HspE7 and Poly-ICLC
- A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory PapillomatosisCompletedPhase 2Nventa Biopharmaceuticals CorporationNCT00038714Written as SGN-00101
Codes
What other systems call verpasep caltespen · ClinicalTrials.gg INT018666
- UNII (FDA) Z7T0JI2E2IVERPASEP CALTESPENOne source FDA
- NCI Thesaurus C2811Verpasep CaltespenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Z7T0JI2E2I | VERPASEP CALTESPEN | One source FDA |
| NCI Thesaurus | C2811 | Verpasep Caltespen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.